Article

Presbyopia-correcting IOLs: Self-rated quality of vision and optical phenomena intensity

Author(s):

Spectacle independence is not the main factor that determines patients’ lens selections, according to study investigators.

Presbyopia-correcting IOLs

A comparison of the quality of the patients’ everyday lifestyle activities and contrast sensitivity found that the 3 lenses fared the same.

German researchers from the Department of Ophthalmology, Goethe-University, Frankfurt am Main, Germany led by Myriam Böhm, MSc, MD, found that diffractive extended-depth-of-focus (EDOF), trifocal, and panfocal multifocal intraocular lenses (MIOLs) all provided good total self-rated quality of vision with mild-to-moderate degrees of optical phenomena under all lighting conditions. The EDOF lenses reportedly causes weaker halos resulting in better nighttime driving.

This prospective comparative case series1 included 108 eyes that had been implanted bilaterally with 1 of the lens types. The investigators assessed the self-rated quality of vision, degree of symptom intensity in 3 lighting conditions, quality of everyday lifestyle activities, spectacle independence, and contrast sensitivity.

IOL assessment

All lenses were found to function well and provided good total self-rated quality of vision in the 3 lighting scenarios.

The patients with the EDOF lens reported slightly better total quality of vision as measured on the Visual Analog Scale: EDOF lens, 9.8±6.67; trifocal lens, 22.2±7.09; and panfocal lens, 19.6±16.25, a difference that reached significance (p=0.041).

Similar percentages of patients reported optical phenomena that did not differ among the 3 lenses (p>0.05) and the degree of the optical symptoms were considered mild-to-moderate in the 3 lighting conditions, but the EDOF lenses were considered to have a significantly (p<0.05) lower intensity of halos compared with the other lenses.

A comparison of the quality of the patients’ everyday lifestyle activities and contrast sensitivity found that the 3 lenses fared the same. All patients with panfocal and trifocal lenes were spectacle independent. While 44% of the patients with the EDOF lens needed reading glasses, all reported that they would opt for the same lens again despite the need for reading glasses. This indicated that spectacle independence is not the main factor that determines patients’ lens selections, according to the investigators.

Reference
  1. Böhm M, Hemkeppler E, Kohnen T. Self-rated quality of vision and optical phenomena intensity of diffractive presbyopia-correcting intraocular lenses. EDOF, trifocal versus panfocal. J Cataract Refract Surg. 2021;doi: 10.1097/j.jcrs.0000000000000862

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
© 2025 MJH Life Sciences

All rights reserved.